Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice

Parasitology Research

Volumn 112, Issue 11, 2013, Pages 3859-3863

  Payne, Amanda J ^a   Neal, Lori M ^a   Knoll, Laura J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMAZINE; FUSIDIC ACID; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG RESEARCH; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LISTERIA MONOCYTOGENES; LIVER; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TISSUE CULTURE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

BACTERIA (MICROORGANISMS); LISTERIA MONOCYTOGENES; MUS; PLASMODIUM FALCIPARUM; TOXOPLASMA GONDII;

ANIMAL STRUCTURES; ANIMALS; ANTI-INFECTIVE AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FUSIDIC ACID; LISTERIA MONOCYTOGENES; LISTERIOSIS; MICE; MICROBIAL SENSITIVITY TESTS; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; SURVIVAL ANALYSIS; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; TREATMENT FAILURE;

EID: 84887224619     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-013-3574-1     Document Type: Article

References (15)

1. Bellahsene A, Forsgren A (1980) Effect of fusidic acid on the immune response in mice. Infect Immun 29(3):873-878
2. Black FT, Wildfang IL, Borgbjerg K (1985) Activity of fusidic acid against Plasmodium falciparum in vitro. Lancet 1(8428):578-579
3. Collignon P, Turnidge J (1999) Fusidic acid in vitro activity. Int J Antimicrob Agents 12(Suppl 2):S45-S58
4. Denkers EY, Gazzinelli RT (1998) Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 11(4):569-588
5. Findon G, Miller TE, Rowe LC (1991) Pharmacokinetics of fusidic acid in laboratory animals. Lab Anim Sci 41(5):462-465
6. Kinoshita T, Kawano G, Tanaka N (1968) Association of fusidic acid sensitivity with G factor in a protein-synthesizing system. Biochem Biophys Res Commun 33(5):769-773
7. Kraus CN, Burnstead BW (2011) The safety record of fusidic acid in non-US markets: a focus on skin infections. Clin Infect Dis 52(Suppl 7):S527-S537. doi: 10.1093/cid/cir168
8. Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363(9425):1965-1976. doi: 10.1016/S0140-6736(04)16412-X
9. Nicoletti F, Zaccone P, Di Marco R, Magro G, Grasso S, Morrone S, Santoni A, Tempera G, Meroni PL, Bendtzen K (1995) Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology 85(4):645-650
10. Osaili TM, Al-Nabulsi AA, Taha MH, Al-Holy MA, Alaboudi AR, Al-Rousan WM, Shaker RR (2012) Occurrence and antimicrobial susceptibility of Listeria monocytogenes isolated from brined white cheese in Jordan. J Food Sci 77(9):M528-M532. doi: 10.1111/j.1750-3841.2012.02877.x
11. Payne TM, Payne AJ, Knoll LJ (2011) A Toxoplasma gondii mutant highlights the importance of translational regulation in the apicoplast during animal infection. Mol Microbiol 82(5):1204-1216. doi: 10.1111/j.1365-2958.2011.07879.x
12. Rowe L, Findon G, Miller TE (1992) An experimental evaluation of the pharmacokinetics of fusidic acid in peritoneal dialysis. J Med Microbiol 36(2):71-77
13. Tobin CM, Knoll LJ (2012) A patatin-like protein protects Toxoplasma gondii from degradation in a nitric oxide-dependent manner. Infect Immun 80(1):55-61. doi: 10.1128/IAI.05543-11
14. Troxler R, von Graevenitz A, Funke G, Wiedemann B, Stock I (2000) Natural antibiotic susceptibility of Listeria species: L. grayi, L. innocua, L. ivanovii, L. monocytogenes, L. seeligeri and L. welshimeri strains. Clin Microbiol Infect 6(10):525-535
15. Turnidge J (1999) Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 12(Suppl 2):S23-S34